Peptinov is a biotechnology company based in Paris, France, specializing in immunotherapy for chronic inflammatory diseases. They develop peptide-based immunotherapies by inducing the production of anti-cytokine antibodies in patients. Their unique R&D platform uses bioinformatics and molecular modeling to design peptide sequences, which can be applied to any crystallized protein. Peptinov's most advanced product targets IL-6 and will soon enter clinical development.